Compare BTG & BLCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BTG | BLCO |
|---|---|---|
| Founded | 2006 | 1853 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Precious Metals | Ophthalmic Goods |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9B | 5.9B |
| IPO Year | N/A | 2022 |
| Metric | BTG | BLCO |
|---|---|---|
| Price | $5.41 | $16.97 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 2 | 13 |
| Target Price | $6.00 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 50.2M | 322.8K |
| Earning Date | 02-18-2026 | 02-18-2026 |
| Dividend Yield | ★ 1.47% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | $2,507,049,000.00 | ★ $4,976,000,000.00 |
| Revenue This Year | $68.08 | $8.06 |
| Revenue Next Year | $22.77 | $5.81 |
| P/E Ratio | $35.14 | ★ N/A |
| Revenue Growth | ★ 30.97 | 6.23 |
| 52 Week Low | $2.50 | $10.45 |
| 52 Week High | $5.94 | $17.86 |
| Indicator | BTG | BLCO |
|---|---|---|
| Relative Strength Index (RSI) | 59.53 | 52.73 |
| Support Level | $4.71 | $16.17 |
| Resistance Level | $5.15 | $17.13 |
| Average True Range (ATR) | 0.31 | 0.43 |
| MACD | -0.02 | -0.03 |
| Stochastic Oscillator | 58.33 | 60.58 |
B2Gold Corp is an international, low-cost, senior gold mining company. It has three operating open-pit gold mines in Mali, Namibia, and the Philippines and numerous exploration projects across four continents. Other assets include the Gramalote and Kiaka gold projects. The company focuses on acquiring and developing interests in mineral properties with a primary focus on gold deposits as gold production forms all its revenue. There is no dependence on a particular purchaser because the gold is sold into various markets. The company's reportable operating segments include its mining operations and development projects, namely Fekola; Masbate; Otjikoto; the Goose Project, and other mineral properties; and corporate and other.
Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.